Clinical TrialsPaid Clinical Trials in Alabama
Reviewed by Michael Gill, B. Sc.
Image of Auburn University in Auburn, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

TMS Afor ethanol

18+
All Sexes
The purpose of this study is to help understand how attention processes influence brain engagement during emotion and social cognition. The investigators also want to know if these processes are associated with drinking alcohol. Participation includes three study visits of about 2 hours each over approximately a month. The first visit involves a magnetic resonance imaging (MRI) scan and answering survey questions. Each of the next two visits will involve a session of transcranial magnetic stimulation (TMS, a non-invasive brain stimulation technique) followed by another MRI scan. People in the Auburn/Opelika area 19 or older are eligible to participate. People who drink alcohol and people who do not drink or don't drink very much are invited to participate.
Recruiting
Has No Placebo
Auburn UniversitySamantha J Fede, PhD
Image of UAB/Lakeshore Research Collaborative in Birmingham, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

EM2Mfor Spina Bifida

18+
All Sexes
This trial is testing the effects of an innovative exercise program, movement-2-music (M2M), on health and fitness outcomes in adults with physical/mobility disabilities. One hundred and eight participants will be recruited and randomly enrolled into one of two groups: M2M or waitlist control. The primary aim of this study is to determine the effects of the 12-week M2M program on health and fitness in participants with physical/mobility disabilities. The study will also compare the observed effects of the program to a previous M2M study, and test whether adherence (attendance to the 12-week program) affects the
Recruiting
Quick Reply
Has No Placebo
UAB/Lakeshore Research Collaborative (+1 Sites)
Image of ForCare Clinical Research in Tampa, United States.
Phase-Based Progress Estimates
2
Effectiveness
3
Safety

Abrocitinib 100 Mgfor Eczema, Infantile

Any Age
All Sexes
This trial is studying whether a new drug, abrocitinib, is effective and safe for treating atopic dermatitis in patients aged 12 years and older. The trial consists of an initial treatment period of 92 weeks, followed by a secondary treatment period of variable length during which subjects will receive treatment with open-label abrocitinib until availability of commercial product in their country, or until the sponsor terminates the study in that country. There is also a sub-study evaluating whether abrocitinib has any potential effects on adolescent bone with regard to abnormal bone findings in knee MRI.
Phase 3
Waitlist Available
ForCare Clinical Research (+8 Sites)Pfizer CT.gov Call CenterPfizer
25 Paid Studies Alabama Near Me
Top Cities for Paid Studies Alabama
Image of Birmingham in Alabama.
Birmingham
189Active Trials
University of Alabama at BirminghamTop Active Site
Image of Miami in Florida.
Miami
138Active Trials
University of Miami Miller School of Medicine-Sylvester Cancer CenterTop Active Site